Min Min Yang
Chief Executive Officer at PHARMABLOCK SCIENCES (NANJING), INC.
Net worth: 179 M $ as of 30/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Juan Juan Wu | F | 47 | 16 years | |
| Cun Xiang Ju | M | 40 | 6 years | |
| Zhong Yu Li | F | 60 | 7 years | |
| Jing Wei Zhu | M | 41 | 10 years | |
| Zheng Wu | M | 60 |
Shanghai Ark Biopharmaceutical Co., Ltd.
 Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | 10 years |
| Bo Yu | M | 54 | 4 years | |
| Juan Du | F | 42 | 4 years | |
| Jie Cai | M | 43 | 12 years | |
| Shan Bao Yu | M | 42 | 13 years | |
| Yun Bin Gao | M | 57 | 6 years | |
| Hui Xin Yang | F | 43 | 13 years | |
| Jing Zhao | M | 43 | 6 years | |
| Xiang Gao | M | 61 | 7 years | |
| Tao Wang | M | 39 | 1 years | |
| Xu Wei Zheng | M | 60 | 5 years | |
| Bin Qing Xiao | M | 45 | 4 years | |
| Wen Fang Wu | M | 45 |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | 3 years |
| Sen Quan Zhang | M | 47 |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | 3 years |
| Chong Bo Xu | M | 41 | 2 years | |
| Li Jin | M | 51 | 3 years | |
| Shu Qiang Zhang | M | 42 | 16 years | |
| Tao Wen | M | 45 | 4 years | |
| Yiou Wang | M | 40 | 1 years | |
| Xu Bo Hu | M | 48 |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | 4 years |
| Hai Qing Yuan | M | 58 |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | - |
| Audrey Rao | F | 61 |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | 3 years |
| Yuan Ping Jie | M | 58 | 1 years | |
| Yi Fei Wu | F | 45 | 3 years | |
| Wen Bing Su | M | 59 |
Nanjing University
| 27 years |
| De Rong Leng | M | 61 | 1 years | |
| Kun Rong Shen | M | 61 |
Nanjing University
| 26 years |
| Xu Yu Zhang | M | 60 |
Nanjing University
| 26 years |
| Jin Lu | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Xi Han Wu | M | 56 | 13 years | |
| Shijie Zhang | M | 60 | - | |
| Shuhai Zhao | M | 61 | - | |
| Matt Garibaldi | M | - |
Auburn University
| 5 years |
| Zhen Dong Wu | M | 47 | - | |
| Yong Mei Zeng | F | 55 | - | |
| Ya Ling Liu | M | 57 | - | |
| Scott Sealock | M | - |
Auburn University
| 5 years |
| Wei Biao Wang | M | 54 |
Nanjing University
| 7 years |
| Hai Jun Dong | M | 60 | - | |
| De Chao Yu | M | 61 | 3 years | |
| Wenfang Miao | M | - | - | |
| Ling Lai Wang | M | 52 |
Nanjing University
| 1 years |
| Yi Jin | F | 49 |
Nanjing University
| 4 years |
| Cheng Xiang Shen | M | 49 |
Nanjing University
| 4 years |
| Shun Huang | M | 50 |
Nanjing University
| 4 years |
| Wan Liang Wu | M | 60 | - | |
| Rhett Lambert | M | - |
Auburn University
| 4 years |
| Yuan Kun Cao | M | 58 |
Nanjing University
| 3 years |
| Craig Michael Covington | M | - |
Auburn University
| 5 years |
| Stan Lewis | M | - |
Auburn University
| 4 years |
| Peng Rui | M | 43 |
Nanjing University
| 4 years |
| William Wood | M | 46 |
Auburn University
| 4 years |
| Liang Zhao | M | 45 |
Nanjing University
| 4 years |
| Zhengtian Gu | M | - | - | |
| Kun Yang | M | 49 |
Nanjing University
| 4 years |
| Blake Luse | M | - |
Auburn University
| 4 years |
| Jian Rong Liu | M | 45 |
Nanjing University
| 4 years |
| Leslie Bonnikson | F | - |
Auburn University
| 3 years |
| Jian Hua Zhao | M | 41 |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | - |
| Dan Liu | M | 41 | 4 years | |
| Yu Lin Wang | M | 59 |
Nanjing University
| 1 years |
| Juan Chen | F | 43 | - | |
| Hong Bao Wei | M | 51 |
Nanjing University
| 4 years |
| Jason Sims | M | - |
Auburn University
| 4 years |
| Phillip Cook | M | - |
Auburn University
| 4 years |
| Han Qiu | F | 49 |
Nanjing University
| 4 years |
| Marshall P. Green | M | - |
Auburn University
| 4 years |
| Chase Mulvehill | M | - |
Auburn University
| 4 years |
| Yang Chen | M | 43 |
Nanjing University
| 4 years |
| Chong Xu | M | 48 |
Nanjing University
| 4 years |
| Elliot Cunningham | M | - |
Auburn University
| 4 years |
| Mark Hamilton | M | - |
Auburn University
| 4 years |
| Burke Cox | M | - |
Auburn University
| 4 years |
| Brent Reilly | M | - |
Auburn University
| 4 years |
| Brandon Ramsey | M | - |
Auburn University
| 4 years |
| Yu Bo Lian | M | 60 |
Nanjing University
| 2 years |
| Tyler Hedges | M | - |
Auburn University
| 2 years |
| Sean Flinn | M | - |
Auburn University
| 4 years |
| Yong Cao | M | 65 |
Nanjing University
| 2 years |
| Wade A. Monroe | M | - |
Auburn University
| 4 years |
| Chang Chun Li | M | 53 |
Nanjing University
| 3 years |
| Wesley D. Fountain | M | - |
Auburn University
| 2 years |
| Chris McGregor | M | - |
Auburn University
| 5 years |
| Coby Stockard Kutcher | F | - |
Auburn University
| 4 years |
| Katie Windham | F | - |
Auburn University
| 4 years |
| Jian Guo Wang | M | 64 |
Nanjing University
| 2 years |
| Kelly Marino | F | - |
Auburn University
| 4 years |
| Jamie Uertz | M | - |
Auburn University
| 4 years |
| Leo John Calagaz | M | - |
Auburn University
| 4 years |
| Gary Johnson | M | - |
Auburn University
| 2 years |
| Ryan Jones | M | - |
Auburn University
| 3 years |
| Krishna Vinjamuri | M | - |
Auburn University
| 2 years |
| Kevin Fienup | M | - |
Auburn University
| 4 years |
| Gregory A. Gaddy | M | - |
Auburn University
| 3 years |
| Becca Harper | F | - |
Auburn University
| 4 years |
| Tong Liu | M | - |
Nanjing University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| China | 67 | 67.00% |
| United States | 33 | 33.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Min Min Yang
- Personal Network
